Aquestive Therapeutics, Inc. $AQST Stake Trimmed by Sei Investments Co.

Sei Investments Co. lessened its stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 87.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 24,845 shares of the company’s stock after selling 173,143 shares during the period. Sei Investments Co.’s holdings in Aquestive Therapeutics were worth $103,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Walleye Capital LLC lifted its stake in Aquestive Therapeutics by 103.3% during the first quarter. Walleye Capital LLC now owns 584,977 shares of the company’s stock valued at $2,428,000 after buying an additional 297,166 shares in the last quarter. Independent Financial Group LLC acquired a new stake in shares of Aquestive Therapeutics during the first quarter valued at approximately $65,000. Wealthfront Advisers LLC acquired a new stake in shares of Aquestive Therapeutics during the first quarter valued at approximately $50,000. Bleakley Financial Group LLC purchased a new stake in shares of Aquestive Therapeutics in the 1st quarter valued at approximately $563,000. Finally, International Assets Investment Management LLC lifted its position in shares of Aquestive Therapeutics by 27.0% in the 1st quarter. International Assets Investment Management LLC now owns 22,895 shares of the company’s stock valued at $95,000 after acquiring an additional 4,870 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on AQST shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Friday, July 17th. Wall Street Zen lowered Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Oppenheimer assumed coverage on Aquestive Therapeutics in a research report on Friday, April 24th. They issued an “outperform” rating and a $8.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $8.50.

Insider Activity

In other news, Director Julie Krop sold 25,000 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total transaction of $125,500.00. Following the transaction, the director directly owned 25,000 shares in the company, valued at $125,500. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is owned by company insiders.

Aquestive Therapeutics Price Performance

Shares of AQST opened at $4.32 on Wednesday. The company has a market capitalization of $542.20 million, a price-to-earnings ratio of -6.65 and a beta of 1.49. The business’s 50-day moving average is $4.15 and its 200-day moving average is $4.10. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.93 and a fifty-two week high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The company had revenue of $13.82 million for the quarter, compared to analysts’ expectations of $11.42 million. Equities research analysts expect that Aquestive Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.